NewPace develops a flexible and subcutaneous implantable cardioverter defibrillator (ICD) with no leads within the heart with a wireless rechargeable battery and Bluetooth communication.
The NewPace defibrillator differs from standard ICDs in that it does not have leads in the heart. The rechargeable device is implanted subcutaneously with no need for fluoroscopy and communicates via Bluetooth with a smartphone. The string-shaped defibrillator requires one hour per year for wireless recharge and communicates at low energy with smartphones for monitoring. The subcutaneous implantation requires no in-patient care.
NewPace partners with China-based Haisco Pharmaceutical.
Cumulative Funding Raised Over Time ($)
Employees Over Time
Newpace Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
Jun 28, 2021
www.prnewswire.com
NewPace Selects Wireless Power Market Leader Powermat Technologies to Develop Advanced Wireless Charging Technology for Innovative Life-Saving Devices
#Partners
Jun 9, 2017
cardiacrhythmnews.com
HRS 2017: New implantable string subcutaneous defibrillator shows promise for sudden cardiac death prevention - Cardiac Rhythm News
#Customers #Expand
May 16, 2017
www.dicardiology.com
Novel String-Shaped Subcutaneous ICD Proves Effective in Patients